Self-reported symptom study of COVID-19 chemosensory dysfunction in Malaysia.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Corporate Authors:
      Malaysian COVID-19 Anosmia Research Group
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      COVID-19 Nucleic Acid Testing* ; Olfaction Disorders*/diagnosis ; Olfaction Disorders*/epidemiology ; Olfaction Disorders*/etiology ; Olfaction Disorders*/physiopathology ; SARS-CoV-2* ; Self Report* ; Surveys and Questionnaires* ; Taste Disorders*/diagnosis ; Taste Disorders*/epidemiology ; Taste Disorders*/etiology ; Taste Disorders*/physiopathology; Adolescent ; Adult ; Aged ; Aged, 80 and over ; COVID-19/complications ; COVID-19/diagnosis ; COVID-19/epidemiology ; COVID-19/physiopathology ; Female ; Humans ; Malaysia/epidemiology ; Male ; Middle Aged
    • Abstract:
      Alterations in the three chemosensory modalities-smell, taste, and chemesthesis-have been implicated in Coronavirus Disease 2019 (COVID-19), yet emerging data suggest a wide geographic and ethnic variation in the prevalence of these symptoms. Studies on chemosensory disorders in COVID-19 have predominantly focused on Caucasian populations whereas Asians remain understudied. We conducted a nationwide, multicentre cross-sectional study using an online questionnaire on a cohort of RT-PCR-confirmed adult COVID-19 patients in Malaysia between 6 June and 30 November 2020. The aim of our study was to investigate their presenting symptoms and assess their chemosensory function using self-ratings of perceived smell, taste, chemesthesis, and nasal blockage. In this cohort of 498 patients, 41.4% reported smell and/or taste loss when diagnosed with COVID-19, which was the commonest symptom. Blocked nose, loss of appetite, and gastrointestinal disturbances were independent predictors of smell and/or taste loss on multivariate analysis. Self-ratings of chemosensory function revealed a reduction in smell, taste, and chemesthesis across the entire cohort of patients that was more profound among those reporting smell and/or taste loss as their presenting symptom. Perceived nasal obstruction accounted for only a small proportion of changes in smell and taste, but not for chemesthesis, supporting viral disruption of sensorineural mechanisms as the dominant aetiology of chemosensory dysfunction. Our study suggests that chemosensory dysfunction in COVID-19 is more widespread than previously reported among Asians and may be related to the infectivity of viral strains.Study Registration: NMRR-20-934-54803 and NCT04390165.
      (© 2022. The Author(s).)
    • References:
      Clin Infect Dis. 2020 Jul 28;71(15):889-890. (PMID: 32215618)
      Med J Malaysia. 2020 Sep;75(5):582-584. (PMID: 32918430)
      ACS Chem Neurosci. 2020 Oct 21;11(20):3180-3184. (PMID: 32997488)
      N Engl J Med. 2020 Jun 11;382(24):2372-2374. (PMID: 32302078)
      Trends Cogn Sci. 2021 Feb;25(2):111-123. (PMID: 33349546)
      Head Neck. 2020 Jul;42(7):1560-1569. (PMID: 32437022)
      Chem Senses. 2021 Jan 1;46:. (PMID: 33367502)
      ACS Chem Neurosci. 2020 Sep 2;11(17):2774-2781. (PMID: 32786309)
      Otolaryngol Head Neck Surg. 2020 Jul;163(1):132-134. (PMID: 32340555)
      Philos Trans R Soc Lond B Biol Sci. 2018 Aug 5;373(1752):. (PMID: 29915007)
      J Korean Med Sci. 2020 May 11;35(18):e174. (PMID: 32383370)
      ACS Chem Neurosci. 2020 Oct 7;11(19):2944-2961. (PMID: 32870641)
      JAMA. 2020 May 26;323(20):2089-2090. (PMID: 32320008)
      Sci Rep. 2021 Sep 1;11(1):17504. (PMID: 34471196)
      N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013)
      ACS Chem Neurosci. 2021 Oct 6;12(19):3535-3549. (PMID: 34533304)
      Acta Neuropathol. 2021 Jun;141(6):809-822. (PMID: 33903954)
      Ann Otol Rhinol Laryngol. 2021 May;130(5):513-519. (PMID: 33025798)
      Rev Endocr Metab Disord. 2016 Jun;17(2):221-40. (PMID: 27287364)
      Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261. (PMID: 32253535)
      Rhinology. 2021 Feb 1;59(1):26-31. (PMID: 33320115)
      Eur Arch Otorhinolaryngol. 2021 Sep;278(9):3375-3380. (PMID: 33595697)
      ACS Chem Neurosci. 2020 Jun 3;11(11):1555-1562. (PMID: 32379417)
      Laryngoscope. 2021 Mar;131(3):E932-E939. (PMID: 32940922)
      Int Forum Allergy Rhinol. 2020 Aug;10(8):944-950. (PMID: 32301284)
      medRxiv. 2020 Sep 01;:. (PMID: 32908992)
      Int Forum Allergy Rhinol. 2020 Sep;10(9):1105-1107. (PMID: 32613712)
      Brain Behav Immun Health. 2021 Aug;15:100268. (PMID: 34027497)
      Chem Senses. 2020 Oct 9;45(7):609-622. (PMID: 32564071)
      Mater Today Proc. 2022;48:828-836. (PMID: 33680867)
      Sci Adv. 2021 Mar 19;7(12):. (PMID: 33741586)
      Chem Senses. 2019 Jul 17;44(6):357-364. (PMID: 31077277)
      PLoS Negl Trop Dis. 2020 Nov 30;14(11):e0008744. (PMID: 33253226)
      Eur Arch Otorhinolaryngol. 2021 Sep;278(9):3595-3596. (PMID: 34185144)
      J Clin Oncol. 2004 Sep 1;22(17):3485-90. (PMID: 15337796)
      Lancet Oncol. 2006 Nov;7(11):903-9. (PMID: 17081915)
      Nature. 2021 Jan;589(7843):603-607. (PMID: 33166988)
      Ann Intern Med. 2020 Oct 20;173(8):672-675. (PMID: 32449883)
      Nat Med. 2020 Jul;26(7):1037-1040. (PMID: 32393804)
      Sci Adv. 2020 Jul 31;6(31):. (PMID: 32937591)
      Eur Arch Otorhinolaryngol. 2021 Jun;278(6):1853-1862. (PMID: 33159556)
      Int J Oral Sci. 2020 Feb 24;12(1):8. (PMID: 32094336)
      Nat Med. 2020 May;26(5):681-687. (PMID: 32327758)
      JAMA Otolaryngol Head Neck Surg. 2020 Jul 1;146(7):674-675. (PMID: 32267483)
      BMC Public Health. 2013 Mar 21;13:251. (PMID: 23517342)
      Lancet Reg Health West Pac. 2020 Nov;4:100055. (PMID: 33521741)
      Gastroenterology. 2020 May;158(6):1831-1833.e3. (PMID: 32142773)
      Iran J Otorhinolaryngol. 2020 Jul;32(111):213-222. (PMID: 32850509)
      JAMA Neurol. 2020 Jun 1;77(6):683-690. (PMID: 32275288)
    • Contributed Indexing:
      Investigator: NA Bachok; L Sim; T Ti; TH Lee; SNA Mohd Nor; KS Tay; A Gouri Pagan; A Aman; K Mohamed Awang; JN Salleh; H Manickam; N Mohamad Zaki; CK Moh; R Thurairaju; HH Yee; N Abd Aziz; R Ramli; R Mohd Noor; A Mat Jelani; MF Alimi Mustapha; AA Ab Aziry; K Lohanadan; SF Abdul Razak; YT Saw; JHL Kong; CSL Teh; KK Prem Singh; A Karunakaran; N Rajendram; NK Nik Mohd; NA Ja'afar; SS Che Mohd Razali; S Baskaran; FH Hassan; K Thuraisingam; H Hithayathullah; PK Manjeet Singh; SH Lee; NH Zainul; MC Ooi; SA Mahadzir; NA Mohd Yusoff; AF Mohamad Illiayas; YS Tan; I Ismail; HK Chan; J Saniasiaya; TK Ng; K Ramasamy; FF Mohd Saifuddin
    • Molecular Sequence:
      ClinicalTrials.gov NCT04390165
    • Publication Date:
      Date Created: 20220209 Date Completed: 20220214 Latest Revision: 20231103
    • Publication Date:
      20231215
    • Accession Number:
      PMC8826975
    • Accession Number:
      10.1038/s41598-022-06029-6
    • Accession Number:
      35136124